Fragment-Based Drug Discovery Down Under Conference 2022
The Fragment-Based Drug Discovery Down Under Conference 2022, sponsored by Dotmatics and held at Monash Institute of Pharmaceutical Sciences in Melbourne from September 28-30, gathered multidisciplinary experts from academia and industry to discuss advances in fragment-based drug design through workshops, talks, presentations, and social events covering topics such as library design, fragment screening, structural biology, computational chemistry, and fragment-to-lead development.
Dotmatics sponsored the fourth Fragment-Based Drug Discovery Down Under Meeting (FBDD-DU3) at the Monash Institute of Pharmaceutical Sciences in Melbourne from September 28 to 30, 2022.
The 2022 conference brought together a multidisciplinary group of biologists, biochemists, biophysicists, and chemists from academia and industry to discuss the latest techniques and progress in the field of fragment-based drug design.
Conference topics included:
- Library design
- Fragment screening
- Structural biology
- Computation chemistry
- Fragment-to-hit-to-lead chemistry
- Success stories
The FBDD-DU 2022 meeting featured workshops, plenary talks, oral and poster presentation sessions, and social events, including a dinner at the Hotel Railway in Brunswick.
Event Details:
- Date: September 28-30, 2022
- Time: 7:00am AEST
- Location: Monash Institute of Pharmaceutical Sciences (MIPS), Parkville, Australia
Related
Principles and Processes of Early Drug Discovery
The early drug discovery process involves target identification and validation, hit discovery through confirming active compounds, assay development for testing effects, and employs various screening strategies such as high-throughput, virtual, phenotypic, and target-based screening to identify promising drug candidates.
Proventa | Bioinformatics Strategy Meeting - Boston
The Proventa Bioinformatics Strategy Meeting in Cambridge, MA on May 23, 2022, is a patient-centric event featuring personalized agendas with interactive roundtable discussions, one-to-one strategic meetings, and networking opportunities designed to unite industry leaders in advancing the discovery, development, and commercialization of life-saving therapies.
Dotmatics at Lab of the Future, USA
Dotmatics is partnering with Siemens to sponsor the Lab of the Future USA Congress on March 2-3, 2026, in Boston, where Michael Swartz, Dotmatics' Chief Strategy Officer, will present on unifying science, data, and decisions to advance life science research and therapeutics development in the evolving collaborative research environment.
Dotmatics Innovation Showcase 2025
The Dotmatics Innovation Showcase 2025 is a 60-minute virtual event on May 21, 2025, featuring CEO Thomas Swalla, CPO Kalim Saliba, and VP Phil Mounteney presenting the latest advancements and live demos of Dotmatics' Luma platform and core products designed to accelerate scientific discovery and streamline workflows, followed by a Q&A session.
GBX (Annual Drug Discovery to Developments Innovation Forum)
The 14th Annual Global Discovery to Development Innovation Forum (GDDIF), held on May 24-25, 2022 at the Berlin Palace Hotel, is a premier pharmaceutical R&D summit focused on integrated drug discovery, featuring scientific insights and innovations in Medicinal Chemistry, Screening Technologies, ADME, DMPK, Open Innovation, Informatics, AI, and Oncology for pharma decision makers and scientific leaders.
Agility, Flexibility, and Collaboration: The Three Principles That Redefined Post-Pandemic R&D
The COVID-19 pandemic permanently transformed R&D by establishing agility through AI and faster learning cycles, flexibility via adaptive trial methods, and enhanced collaboration through open data and public-private partnerships, setting a new standard for rapid, rigorous, and cooperative scientific innovation in healthcare.